Format

Send to

Choose Destination
Eur Urol. 2016 Oct;70(4):547-548. doi: 10.1016/j.eururo.2016.02.032. Epub 2016 Feb 22.

The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.

Author information

1
Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy; OLV Vattikuti Robotic Surgery Institute, Melle, Belgium.
2
Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.
3
OLV Vattikuti Robotic Surgery Institute, Melle, Belgium.
4
Academic Urology Unit and Institute for Cancer Studies, The Medical School, University of Sheffield, Sheffield, UK.
5
Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy. Electronic address: montorsi.francesco@hsr.it.

Abstract

One of the most effective ways to reduce overtreatment of prostate cancer is to limit its detection in men with low-risk disease. Although many data are currently missing, we foresee a future with reduced prostate-specific antigen (PSA) testing in men selected through baseline PSA values or genetic predisposition. Then selective biopsy using multiparametric magnetic resonance imaging and longitudinal biomarkers will play a role.

PMID:
26916048
DOI:
10.1016/j.eururo.2016.02.032
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center